Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Sees Large Decline in Short Interest

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) was the target of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 1,428,680 shares, a drop of 33.2% from the April 30th total of 2,138,313 shares. Based on an average trading volume of 490,920 shares, the short-interest ratio is presently 2.9 days. Approximately 6.2% of the shares of the company are sold short.

Shares of Anthera Pharmaceuticals traded down $0.01, hitting $0.31, during mid-day trading on Thursday, according to MarketBeat Ratings. 658,100 shares of the company were exchanged, compared to its average volume of 1,994,474. Anthera Pharmaceuticals has a 1-year low of $0.21 and a 1-year high of $2.97. The company has a market cap of $7.62 million, a PE ratio of -0.08 and a beta of 2.69.

A number of brokerages have recently issued reports on ANTH. Zacks Investment Research lowered shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 3rd. ValuEngine upgraded shares of Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 1st. Piper Jaffray Companies lowered shares of Anthera Pharmaceuticals from an “overweight” rating to an “underweight” rating in a research report on Monday, March 12th. HC Wainwright restated a “buy” rating on shares of Anthera Pharmaceuticals in a research report on Tuesday, March 6th. Finally, Roth Capital began coverage on shares of Anthera Pharmaceuticals in a research report on Wednesday, February 21st. They set a “buy” rating and a $10.00 target price on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $3.44.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Armistice Capital LLC acquired a new stake in shares of Anthera Pharmaceuticals during the fourth quarter worth $1,269,000. BVF Inc. IL lifted its holdings in shares of Anthera Pharmaceuticals by 20.9% during the fourth quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock worth $2,007,000 after purchasing an additional 209,896 shares during the period. Finally, 683 Capital Management LLC acquired a new stake in shares of Anthera Pharmaceuticals during the fourth quarter worth $399,000. 7.49% of the stock is owned by hedge funds and other institutional investors.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.

Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply